Stroke outcomes following durable left ventricular assist device implant in patients bridged with micro‐axial flow pump: Insights from a large registry
Guglielmo Gallone,Daniel Lewin,Sebastian Rojas Hernandez,Alexander Bernhardt,Michael Billion,Anna Meyer,Ivan Netuka,J‐J Kooij,Marina Pieri,Mariusz K. Szymanski,Christian H. Moeller,Payam Akhyari,Khalil Jawad,Ihor Krasivskyi,Bastian Schmack,Gloria Färber,Marta Medina,Assad Haneya,Daniel Zimpfer,Gaik Nersesian,Pia Lanmueller,Antonio Spitaleri,Mehmet Oezkur,Ilija Djordjevic,Diyar Saeed,Massimo Boffini,Julia Stein,F. Gustafsson,Anna Mara Scandroglio,Gaetano Maria De Ferrari,Bart Meyns,Steffen Hofmann,Jan Belohlavek,Jan Gummert,Mauro Rinaldi,Evgenij V. Potapov,Antonio Loforte
DOI: https://doi.org/10.1111/aor.14775
2024-05-29
Artificial Organs
Abstract:In a large registry of patients undergoing durable left ventricular assist device (d‐LVAD) implantation following micro‐axial flow‐pump (mAFP) support, the early ischemic stroke incidence was 10.8% and early hemorrhagic stroke 2.9%. Ischemic stroke, while associated with patient‐related factors, did not appear to be modulated by the temporary mechanical circulatory support strategy and the pre‐operative course. Hemorrhagic stroke was associated with both patient‐related factors and several factors related to the mAFP bundle of care, representing potentially actionable treatment targets. Both early ischemic and hemorrhagic strokes were associated with increased 1‐year mortality rate. Background Stroke after durable left ventricular assist device (d‐LVAD) implantation portends high mortality. The incidence of ischemic and hemorrhagic stroke and the impact on stroke outcomes of temporary mechanical circulatory support (tMCS) management among patients requiring bridge to d‐LVAD with micro‐axial flow‐pump (mAFP, Abiomed) is unsettled. Methods Consecutive patients, who underwent d‐LVAD implantation after being bridged with mAFP at 19 institutions, were retrospectively included. The incidence of early ischemic and hemorrhagic stroke after d‐LVAD implantation (<60 days) and association of pre‐d‐LVAD characteristics and peri‐procedural management with a specific focus on tMCS strategies were studied. Results Among 341 patients, who underwent d‐LVAD implantation after mAFP implantation (male gender 83.6%, age 58 [48–65] years, mAFP 5.0/5.5 72.4%), the early ischemic stroke incidence was 10.8% and early hemorrhagic stroke 2.9%. The tMCS characteristics (type of mAFP device and access, support duration, upgrade from intra‐aortic balloon pump, ECMELLA, ECMELLA at d‐LVAD implantation, hemolysis, and bleeding) were not associated with ischemic stroke after d‐LVAD implant. Conversely, the device model (mAFP 2.5/CP vs. mAFP 5.0/5.5: HR 5.6, 95%CI 1.4–22.7, p = 0.015), hemolysis on mAFP support (HR 10.5, 95% CI 1.3–85.3, p = 0.028) and ECMELLA at d‐LVAD implantation (HR 5.0, 95% CI 1.4–18.7, p = 0.016) were associated with increased risk of hemorrhagic stroke after d‐LVAD implantation. Both early ischemic (HR 2.7, 95% CI 1.9–4.5, p
engineering, biomedical,transplantation